Literature DB >> 9021213

Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.

K S Thomson1, S A Chartrand, C C Sanders, S L Block.   

Abstract

An in vitro study of the activity of 15 antibacterial agents against 202 recent pediatric isolates of Streptococcus pneumoniae from urban and rural Nebraska and rural Kentucky identified trovafloxacin, ofloxacin, clindamycin, and vancomycin as the most active agents and equally active against both penicillin-susceptible and--resistant strains. In contrast, six beta-lactams, three macrolides, and trimethoprim-sulfamethoxazole were less active overall, especially against penicillin-intermediate and--resistant strains. Trovafloxacin inhibited all strains at a concentration of < or = 0.25 micrograms/ml and was 8- to 16-fold more potent than ofloxacin or ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021213      PMCID: PMC163735     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 2.  New prospects for antibacterial agents against multidrug-resistant pneumococci.

Authors:  P C Appelbaum
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

3.  Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986.

Authors:  K P Klugman; H J Koornhof
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

4.  Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment.

Authors:  C T Nelson; E O Mason; S L Kaplan
Journal:  Pediatr Infect Dis J       Date:  1994-07       Impact factor: 2.129

6.  A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.

Authors:  Y C Yee; C Thornsberry; S D Brown; S K Bouchillon; J K Marler; T Rich
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

7.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 8.  USA resistance patterns among UTI pathogens.

Authors:  K S Thomson; W E Sanders; C C Sanders
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

9.  In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

Authors:  A L Barry; M A Pfaller; P C Fuchs; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use.

Authors:  E O Mason; S L Kaplan; L B Lamberth; J Tillman
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more
  14 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 4.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

5.  Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.

Authors:  Keith M Olsen; Martha Gentry-Nielsen; Mei Yue; Mary U Snitily; Laurel C Preheim
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

7.  Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.

Authors:  J S Bradley; G L Kearns; M D Reed; E V Capparelli; J Vincent
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

8.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

9.  Clinical evaluation of the tolerability and efficacy of trovafloxacin compared with sparfloxacin in the treatment of lower respiratory tract infections.

Authors:  J C Shobha; T R Kumar; N Deivanayagam; R B Singh; P Waghray; P A Babu; J Bhaduri; C C Sekhar
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

10.  Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.

Authors:  James A Karlowsky; Clyde Thornsberry; Ian A Critchley; Mark E Jones; Alan T Evangelista; Gary J Noel; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.